These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21534944)

  • 1. Phase analysis identifies compound heterozygous deletions of the PARK2 gene in patients with early-onset Parkinson disease.
    Kim SY; Seong MW; Jeon BS; Kim SY; Ko HS; Kim JY; Park SS
    Clin Genet; 2012 Jul; 82(1):77-82. PubMed ID: 21534944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease.
    Choi JM; Woo MS; Ma HI; Kang SY; Sung YH; Yong SW; Chung SJ; Kim JS; Shin HW; Lyoo CH; Lee PH; Baik JS; Kim SJ; Park MY; Sohn YH; Kim JH; Kim JW; Lee MS; Lee MC; Kim DH; Kim YJ
    Neurogenetics; 2008 Oct; 9(4):263-9. PubMed ID: 18704525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of mutations in the PARK2, PINK1, PARK7 genes in Polish early-onset Parkinson disease patients.
    Koziorowski D; Hoffman-Zacharska D; Sławek J; Jamrozik Z; Janik P; Potulska-Chromik A; Roszmann A; Tataj R; Bal J; Friedman A
    Neurol Neurochir Pol; 2013; 47(4):319-24. PubMed ID: 23986421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Han Chinese family with early-onset Parkinson's disease carries novel compound heterozygous mutations in the PARK2 gene.
    Huang T; Gao CY; Wu L; Gong PY; Wang JZ; Tian YY; Zhang YD
    Brain Behav; 2019 Sep; 9(9):e01372. PubMed ID: 31386307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early-onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients.
    Djarmati A; Hedrich K; Svetel M; Schäfer N; Juric V; Vukosavic S; Hering R; Riess O; Romac S; Klein C; Kostic V
    Hum Mutat; 2004 May; 23(5):525. PubMed ID: 15108293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic mutations in early-onset Parkinson's disease Mexican patients: molecular testing implications.
    Monroy-Jaramillo N; Guerrero-Camacho JL; Rodríguez-Violante M; Boll-Woehrlen MC; Yescas-Gómez P; Alonso-Vilatela ME; López-López M
    Am J Med Genet B Neuropsychiatr Genet; 2014 Apr; 165B(3):235-44. PubMed ID: 24677602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease.
    Hedrich K; Djarmati A; Schäfer N; Hering R; Wellenbrock C; Weiss PH; Hilker R; Vieregge P; Ozelius LJ; Heutink P; Bonifati V; Schwinger E; Lang AE; Noth J; Bressman SB; Pramstaller PP; Riess O; Klein C
    Neurology; 2004 Feb; 62(3):389-94. PubMed ID: 14872018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Exon Dosage Using Multiplex Ligation-Dependent Probe Amplification in Chinese Patients with Early-Onset Parkinson's Disease.
    Lin Y; Zeng YF; Cai NQ; Lin XZ; Wang N; He J
    Eur Neurol; 2019; 81(5-6):246-253. PubMed ID: 31618739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable PARK2 Mutations Cause Early-Onset Parkinson's Disease in a Small Restricted Population.
    Ben-Shachar S; Afawi Z; Masalha R; Badarny S; Neiman T; Pavzner D; Bar-Shira A; Orr-Urtreger A
    J Mol Neurosci; 2017 Oct; 63(2):216-222. PubMed ID: 28913705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations.
    Elfferich P; Verleun-Mooijman MC; Maat-Kievit JA; van de Warrenburg BP; Abdo WF; Eshuis SA; Leenders KL; Hovestadt A; Zijlmans JC; Stroy JP; van Swieten JC; Boon AJ; van Engelen K; Verschuuren-Bemelmans CC; Lesnik-Oberstein SA; Tassorelli C; Lopiano L; Bonifati V; Dooijes D; van Minkelen R
    Neurogenetics; 2011 Nov; 12(4):263-71. PubMed ID: 21993715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound heterozygous mutations in PARK2 causing early-onset Parkinson disease: A case report.
    Fang YQ; Mao F; Zhu MJ; Li XH
    Medicine (Baltimore); 2019 Feb; 98(5):e14228. PubMed ID: 30702579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of PARK2 gene exon rearrangements in Russian patients with sporadic Parkinson's disease.
    Semenova EV; Shadrina MI; Slominsky PA; Ivanova-Smolenskaya IA; Bagyeva G; Illarioshkin SN; Limborska SA
    Mov Disord; 2012 Jan; 27(1):139-42. PubMed ID: 21915905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation analysis of PARK2 in a Uyghur family with early-onset Parkinson's disease in Xinjiang, China.
    Li H; Yusufujiang A; Naser S; Zhu Y; Maimaiti M; He X; Bu J; Meng X; Wang M; Li J; Dina B; Yang L; Nayi Z; Dang H; Wang C; Amiti D; Aji A; Yusufu N; Jiao Y; Duan F
    J Neurol Sci; 2014 Jul; 342(1-2):21-4. PubMed ID: 24831986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of mutations in the PARK2 gene in Serbian patients with Parkinson's disease.
    Jankovic MZ; Dobricic V; Kresojevic N; Markovic V; Petrovic I; Svetel M; Pekmezovic T; Novakovic I; Kostic V
    J Neurol Sci; 2018 Oct; 393():27-30. PubMed ID: 30099245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel compound heterozygous mutations in the
    Shi Y; Kawakami H; Zang W; Li G; Zhang J; Xu C
    Brain Behav; 2018 Jan; 8(1):e00901. PubMed ID: 29568695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of compound heterozygous deletions in the parkin gene of fibroblasts in patients with autosomal recessive hereditary parkinsonism (PARK2).
    Nakaso K; Adachi Y; Yasui K; Sakuma K; Nakashima K
    Neurosci Lett; 2006 May; 400(1-2):44-7. PubMed ID: 16517073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exon dosage variations in Brazilian patients with Parkinson's disease: analysis of SNCA, PARKIN, PINK1 and DJ-1 genes.
    Moura KC; Junior MC; de Rosso AL; Nicaretta DH; Pereira JS; José Silva D; Santos-Rebouças CB; Pimentel MM
    Dis Markers; 2012; 32(3):173-8. PubMed ID: 22377733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of the parkin and PINK1 gene in Jordanian families with incidences of young-onset and juvenile parkinsonism.
    Myhre R; Steinkjer S; Stormyr A; Nilsen GL; Abu Zayyad H; Horany K; Nusier MK; Klungland H
    BMC Neurol; 2008 Dec; 8():47. PubMed ID: 19087301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.
    Sun M; Latourelle JC; Wooten GF; Lew MF; Klein C; Shill HA; Golbe LI; Mark MH; Racette BA; Perlmutter JS; Parsian A; Guttman M; Nicholson G; Xu G; Wilk JB; Saint-Hilaire MH; DeStefano AL; Prakash R; Williamson S; Suchowersky O; Labelle N; Growdon JH; Singer C; Watts RL; Goldwurm S; Pezzoli G; Baker KB; Pramstaller PP; Burn DJ; Chinnery PF; Sherman S; Vieregge P; Litvan I; Gillis T; MacDonald ME; Myers RH; Gusella JF
    Arch Neurol; 2006 Jun; 63(6):826-32. PubMed ID: 16769863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second mutation in PARK2 is absent in patients with sporadic Parkinson's disease and heterozygous exonic deletions/duplications in parkin gene.
    Shulskaya MV; Shadrina MI; Fedotova EY; Abramycheva NY; Limborska SA; Illarioshkin SN; Slominsky PA
    Int J Neurosci; 2017 Sep; 127(9):781-784. PubMed ID: 27798970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.